Floatz logo

FAPi-46

Cholangiocarcinoma

University Hospital, BordeauxSmall moleculePhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

92 Active assets in the Cholangiocarcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 3BB
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 3BB
Irinotecan
Jonsson Comprehensive Cancer Center
Phase 3B
Docetaxel
Merck Sharp & Dohme LLC
Phase 2B
ETOMIDATE
Cheju Halla General Hospital
Phase 4B

View all 50 →

Same molecule, other indications

FAPi-46 is also rated in:

amyloidosisDormant
CCC
Indicative ·
53 / 100
View asset →
melanomaDormant
CCC
Indicative ·
53 / 100
View asset →
ductal breast carcinoma in situDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →